Table 3.
Two-year cumulative incidence of cardiac adverse events in patients with primary NSCLC cancer treated with crizotinib (49).
Cardiac Adverse Event | Population | Cumulative incidence rates (95% CI), % |
---|---|---|
Bradycardia | EU | 1.1 (0.0-3.0) |
USA | 16.9 (10.5-24.7) | |
QT interval prolongation related events | EU | 1.0 (0.0-3.1) |
USA | 26.8 (17.6 - 36.9) | |
Cardiac failure | EU | 0.5 (0.0 – 2.1) |
USA | 6.8 (3.4 – 11.7) |